Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human therapeutic antibodies.

C A Borrebaeck1, R Carlsson

  • 1Department of Immunotechnology, Lund University, Sweden. carl.borrebaeck@immun.lth.se

Current Opinion in Pharmacology
|November 17, 2001
PubMed
Summary

Generating high-affinity human antibodies is now feasible. The main challenge lies in selecting effective cancer therapy targets that signal into cells, offering hope for future antibody treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection and characterization of a lectin from non-seed tissue ofPhaseolus vulgaris.

Planta·2013
Same author

Letter: coeliac disease and ischaemic heart disease--a true additional risk factor? Authors' reply.

Alimentary pharmacology & therapeutics·2013
Same author

The characterisation and risk factors of ischaemic heart disease in patients with coeliac disease.

Alimentary pharmacology & therapeutics·2013
Same author

Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis.

Acta psychiatrica Scandinavica·2006
Same author

Patients with ischemic heart disease: quality of life predicts long-term mortality.

Scandinavian cardiovascular journal : SCJ·2005
Same author

Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study.

Scandinavian journal of gastroenterology·2005

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Genetic engineering advances enable high-affinity human antibody generation.
  • Antibody-based therapies show promise in treating autoimmune diseases and cancers.
  • Identifying effective therapeutic targets remains a critical challenge.

Purpose of the Study:

  • To highlight the shift in focus from antibody generation to target selection in therapeutic development.
  • To discuss the importance of intracellular signaling in target molecule selection for antibody therapy.
  • To review recent advancements and future prospects of antibody-based therapeutics.

Main Methods:

  • Review of current literature on antibody engineering and therapeutic applications.
  • Analysis of clinical successes of antibody therapies like rituximab (anti-CD20) and anti-tumor necrosis factor-alpha.
  • Discussion of emerging strategies for identifying and validating novel therapeutic targets.

Main Results:

  • High-affinity human antibody generation is no longer a primary limitation.
  • Intracellularly signaling target molecules are increasingly preferred for therapeutic intervention.
  • Clinical data supports the efficacy of antibody therapies in non-Hodgkin's lymphoma and Crohn's disease.

Conclusions:

  • The future of antibody-based therapy is promising, driven by technological progress and a deeper understanding of mechanisms of action.
  • Effective target selection is paramount for successful antibody-based cancer therapy.
  • Continued research into novel antibody designs and target identification will expand therapeutic options.

Related Experiment Videos